BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 29191971)

  • 1. Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1.
    Peng G; Mills GB
    Clin Cancer Res; 2018 Feb; 24(3):508-510. PubMed ID: 29191971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
    Garsed DW; Alsop K; Fereday S; Emmanuel C; Kennedy CJ; Etemadmoghadam D; Gao B; Gebski V; Garès V; Christie EL; Wouters MCA; Milne K; George J; Patch AM; Li J; Arnau GM; Semple T; Gadipally SR; Chiew YE; Hendley J; Mikeska T; Zapparoli GV; Amarasinghe K; Grimmond SM; Pearson JV; Waddell N; Hung J; Stewart CJR; Sharma R; Allan PE; Rambau PF; McNally O; Mileshkin L; Hamilton A; Ananda S; Grossi M; Cohen PA; Leung YC; Rome RM; Beale P; Blomfield P; Friedlander M; Brand A; Dobrovic A; Köbel M; Harnett P; Nelson BH; Bowtell DDL; deFazio A;
    Clin Cancer Res; 2018 Feb; 24(3):569-580. PubMed ID: 29061645
    [No Abstract]   [Full Text] [Related]  

  • 3. The Rb1 gene inhibits the viability of retinoblastoma cells by regulating homologous recombination.
    Yang Y; Tian S; Brown B; Chen P; Hu H; Xia L; Zhang J; Cai X; Chen Z; Pan X; Ge J; Yu K; Zhuang J
    Int J Mol Med; 2013 Jul; 32(1):137-43. PubMed ID: 23670186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
    Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.
    Fleury H; Carmona E; Morin VG; Meunier L; Masson JY; Tonin PN; Provencher D; Mes-Masson AM
    Oncotarget; 2017 Jun; 8(25):40152-40168. PubMed ID: 27374179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
    Chartron E; Theillet C; Guiu S; Jacot W
    Crit Rev Oncol Hematol; 2019 Jan; 133():58-73. PubMed ID: 30661659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Who are the long-term survivors of high grade serous ovarian cancer?
    Hoppenot C; Eckert MA; Tienda SM; Lengyel E
    Gynecol Oncol; 2018 Jan; 148(1):204-212. PubMed ID: 29128106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer.
    Konstantinopoulos PA; Matulonis UA
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):997-1010. PubMed ID: 30390770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
    Vanderstichele A; Busschaert P; Olbrecht S; Lambrechts D; Vergote I
    Eur J Cancer; 2017 Nov; 86():5-14. PubMed ID: 28950147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
    Cheng JC; Auersperg N; Leung PC
    Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
    Yang SYC; Lheureux S; Karakasis K; Burnier JV; Bruce JP; Clouthier DL; Danesh A; Quevedo R; Dowar M; Hanna Y; Li T; Lu L; Xu W; Clarke BA; Ohashi PS; Shaw PA; Pugh TJ; Oza AM
    Genome Med; 2018 Oct; 10(1):81. PubMed ID: 30382883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
    Nomura H; Kataoka F; Aoki D; Jinno H; Kitagawa Y; Sato Y; Womack C; Wombwell H; Hodgson D; O'Connor M; Harbron C; Yin X
    Cancer Biomark; 2016; 16(1):145-52. PubMed ID: 26577420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 20. Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.
    Ratner ES; Zhu YL; Penketh PG; Berenblum J; Whicker ME; Huang PH; Lee Y; Ishiguro K; Zhu R; Sartorelli AC; Lin ZP
    Br J Cancer; 2016 Mar; 114(7):777-86. PubMed ID: 26964031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.